Furthermore, since platelets have been shown to promote tumor chemoresistance (33, 34), we examined the effect of GPVI–galectin-3 interaction and blocking this interaction by Revacept on chemoresistance in ovarian cancer cells. Here, GP6 is linked to ovarian carcinoma.